Melanotan II vs PT-141: Melanocortin Peptides Compared

Both Melanotan II and PT-141 are synthetic melanocortin receptor agonists — peptides that activate melanocortin-1 (MC1R) and melanocortin-4 (MC4R) receptors. These receptors regulate multiple physiological processes including skin pigmentation, sexual arousal, and appetite. The two peptides differ primarily in their receptor selectivity, duration of action, and side effect profiles. Understanding these differences is critical for patients comparing options, as they have distinct use cases and risk profiles. This comparison focuses on patient-relevant outcomes: efficacy, safety, tolerability, and practical considerations.

Primary uses: Melanotan II (MT-II) was initially developed as a tanning peptide and has been studied for erectile dysfunction (ED) and female sexual dysfunction.

Mechanism: Non-selective melanocortin agonist; activates MC1R (tanning) and MC4R (appetite suppression, sexual arousal).

Evidence for tanning: Limited human studies; animal models and self-reported user data suggest skin darkening without sun exposure. No large randomized controlled trials published.

Evidence for ED: One small open-label trial (2000) showed improvement in ED; mechanism unclear (may involve nitric oxide or dopamine pathways). Very limited human evidence.

Side effects: Nausea (common, especially dose-dependent), spontaneous erections (a feature, not a bug, for some users), darkening of existing moles, possible increased mole count or mole changing color.

Safety concerns: Potential for mole proliferation or dysplasia; theoretical melanoma risk (never proven but mechanism plausible). Long-term human safety data absent.

Dosing: Typically 0.5-1mg subcutaneous injection; effects are dose-dependent.

Availability: Research chemical markets; not FDA-approved or approved elsewhere for any indication.

Cost: $50-150 per month (self-sourced).

Primary uses: PT-141 (bremelanotide) was specifically developed for sexual dysfunction and is the only melanocortin agonist with FDA approval (approved March 2019 for female sexual arousal disorder).

Mechanism: Selective MC4R agonist (less MC1R activation than Melanotan II); this selectivity may reduce tanning side effects.

Evidence for sexual function: FDA approval based on two randomized controlled trials showing modest improvement in sexual arousal and orgasm frequency in women with hypoactive sexual desire disorder (HSDD). Published data in men shows some efficacy but less robust.

Evidence for tanning: Minimal; MC4R selectivity means much less MC1R activation. Little to no tanning reported in clinical trials.

Side effects: Nausea (dose-dependent; 22-40% in trials), facial flushing, darkening of existing birthmarks/moles (less common than MT-II due to reduced MC1R activity), spontaneous erections in men.

Safety profile: Better characterized than Melanotan II because of FDA approval process. Long-term data limited to ~2 years in published trials. Melanoma risk not specifically studied but lower MC1R activation suggests lower risk vs. Melanotan II.

Dosing: 1.75mg subcutaneous injection, administered as-needed (not chronic daily).

Availability: FDA-approved prescription drug (brand name Vyleesi); also available in research chemical markets at lower cost.

Cost: $300-500 per injection (FDA-approved); $30-100 (black market).

Choose Melanotan II if: - You primarily want tanning without sun exposure (only option for this use) - You accept uncertain safety profile and melanoma risk (theoretical but not proven) - You're willing to self-source from research chemical suppliers - You tolerate side effects (nausea, spontaneous erections, mole changes) - Cost is primary concern ($50-150/month vs. $300-500 per PT-141 injection)

Choose PT-141 if: - You have clinically documented sexual dysfunction (HSDD in women; ED in men) - You prefer FDA-approved option with published safety data - You want selective MC4R activity (potentially lower melanoma risk than Melanotan II) - You can access prescription (Vyleesi) or are willing to self-source - Nausea tolerance is acceptable; dosing is as-needed, not daily

Key differences: | Feature | Melanotan II | PT-141 | |---------|-------------|---------| | FDA approved | No | Yes (for female sexual dysfunction) | | Primary use | Tanning + sexual function | Sexual function | | Receptor selectivity | Non-selective (MC1R + MC4R) | MC4R selective | | Tanning efficacy | Yes (modest evidence) | No (minimal tanning) | | Sexual function efficacy | Limited evidence | Moderate evidence | | Nausea incidence | Dose-dependent | 22-40% in trials | | Melanoma risk | Theoretical; unknown | Lower (less MC1R activation) | | Human trial data | Minimal | Moderate (FDA trials) | | Cost (self-sourced) | $50-150/month | $30-100/injection | | Cost (FDA-approved) | N/A | $300-500/injection |

Bottom line: PT-141 is the safer, better-studied option for sexual dysfunction and has FDA approval. Melanotan II is the only option for tanning but carries theoretical melanoma risk. Neither has robust long-term human safety data. PT-141's MC4R selectivity likely makes it the lower-risk choice, especially for non-tanning use.